Skip to main content

Table 1 Laboratory data at baseline

From: Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report

Laboratory data  
Hemoglobin (g/dl) 13.6
Hematocrit (%) 41.2
White blood cells (103/mm3) 6.74
Neutrophils (103/mm3) 4.5
Lymphocytes (103/mm3) 1.6
Platelet count (103/mm3) 170
Aspartate aminotransferase (IU/l) 52
Alanine aminotransferase (ALT) (IU/l) 51
Gamma-glutamyltransferase
(GGT) (IU/l)
31
Alpha-fetoprotein (IU/ml) < 1
Total bilirubin (mg/dL) 0.34
Direct bilirubin (mg/dl) 0.13
Alkaline phosphatase (IU/L) 63
Sodium (mEq/L) 139
Potassium (mEq/L) 4.3
Creatinine (mg/dl) 1
eGFR (CKD-EPI) 79.5
Glucose (mg/dl) 108
Glycated hemoglobin (mmol/mol) 35
Albumin (g/dl) 4.26
HCV-RNA (IU/ml) 7,014,213
anti-HDV positive
anti-HIV negative
Venereal Disease Research Laboratory (VDRL) negative
Tuberculosis (TB)-interferon gamma release assay (IGRA) negative
Prothrombin time – International normalized ratio (INR) 0.94
HBsAg negative
anti-HBs negative
total anti-HBc positive
anti-HBc IgM negative
HBeAg negative
anti-HBe negative
  1. Hepatitis B virus e antigen, hepatitis B virus e antibody, and hepatitis B virus core antibody IgM were performed at week 8 of treatment; hepatitis D virus antibody was performed at week 8 after the end of treatment. anti-HBc hepatitis B virus core antibody, anti-HBe hepatitis B virus e antibody, anti-HBs hepatitis B virus surface antibody, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, eGFR estimated glomerular filtration rate, HBeAg hepatitis B virus e antigen, HBsAg hepatitis B virus surface antigen, HCV hepatitis C virus, HDV hepatitis D virus